-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Plasma Cell Neoplasm
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Plasma Cell Neoplasm Drug Details: Daratumumab ((HuMax-CD38, JNJ-54767414, Darzalex, Dalinvi, Darzalex Faspro) is an...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bortezomib in Plasma Cell Neoplasm
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Bortezomib in Plasma Cell NeoplasmDrug Details:Bortezomib (Velcade) is a dipeptide boronic acid analogue with anti-neoplastic activity....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RD-138 in Plasma Cell Neoplasm
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RD-138 in Plasma Cell Neoplasm Drug Details: RD-138Â is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CHM-0201 in Plasma Cell Neoplasm
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CHM-0201 in Plasma Cell NeoplasmDrug Details:CHM-0201 is under development for the treatment of relapsed/refractory hematological malignancies...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Plasma Gelsolin Replacement For Neuroinflammation in Neuroinflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Recombinant Plasma Gelsolin Replacement For Neuroinflammation in NeuroinflammationDrug Details:Recombinant plasma gelsolin (pGSN) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Plasma Gelsolin Replacement for Infectious Disease in Sepsis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Recombinant Plasma Gelsolin Replacement for Infectious Disease in Sepsis Drug Details: Recombinant plasma gelsolin (pGSN)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ct-0594Cp Car-T Cells in Plasma Cell Neoplasm
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Ct-0594Cp Car-T Cells in Plasma Cell NeoplasmDrug Details:CT-0594CP is under development for the treatment of relapsed,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Plasma Gelsolin Replacement For Cystic Fibrosis And Bronchiectasis in Bronchiectasis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Recombinant Plasma Gelsolin Replacement For Cystic Fibrosis And Bronchiectasis in Bronchiectasis Drug Details:Recombinant plasma gelsolin (pGSN)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Plasma Gelsolin Replacement For Infectious Disease in Acute Lung Injury
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Recombinant Plasma Gelsolin Replacement For Infectious Disease in Acute Lung Injury Drug Details: Recombinant plasma...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Plasma Gelsolin Replacement For Arthritis, Inflammation, Trauma And Burns in Trauma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Recombinant Plasma Gelsolin Replacement For Arthritis, Inflammation, Trauma And Burns in TraumaDrug Details:Recombinant plasma gelsolin is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Plasma Gelsolin Replacement For Arthritis, Inflammation, Trauma And Burns in Burns
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Recombinant Plasma Gelsolin Replacement For Arthritis, Inflammation, Trauma And Burns in Burns Drug Details:Recombinant plasma gelsolin...
-
Sector Analysis
New![]()
Multiple Myeloma Epidemiology Analysis and Forecast to 2032
Multiple Myeloma Vaccines Report Overview In the 8MM, there were 80,305 diagnosed incident cases of multiple myeloma vaccines in 2022. The diagnosed incident cases of multiple myeloma vaccines are expected to register an AGR of more than 1% during 2022-2032. Multiple myeloma (MM) is a hematologic cancer that forms in a type of white blood cell called plasma cells. Normal plasma cells help fight infections by making antibodies that recognize and attack germs, but MM causes cancer cells to accumulate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Donidalorsen Sodium in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Donidalorsen Sodium in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drug Details: Donidalorsen sodium...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-880 in Multifocal Motor Neuropathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-880 in Multifocal Motor Neuropathy Drug Details: TAK-880 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-880 in Primary Immune Deficiency (PID)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-880 in Primary Immune Deficiency (PID) Drug Details: TAK-880 is under development for the treatment...
-
Product Insights
![]()
Infion/ SK Plasma – Jakarta Blood Plasma Fractionation Facility – Jakarta
Equip yourself with the essential tools needed to make informed and profitable decisions with our Infion/ SK Plasma - Jakarta Blood Plasma Fractionation Facility - Jakarta report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Navenibart in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Navenibart in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drug Details: Navenibart (STAR-0215) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Relapsed Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details: Daratumumab ((HuMax-CD38, JNJ-54767414, Darzalex, Dalinvi, Darzalex Faspro)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Felzartamab in Membranous Glomerulonephritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Felzartamab in Membranous Glomerulonephritis Drug Details: Felzartamab is under development for the treatment of late...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Felzartamab in Antibody-Mediated Rejection (AMR)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Felzartamab in Antibody-Mediated Rejection (AMR) Drug Details: Felzartamab is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.